ALK and non-small cell lung carcinoma: Lorlatinib, a third-generation ALK inhibitor, was designed for selective central nervous system (CNS) penetration.[5,6] Lorlatinib exerts potent antitumor activity against tumors that are resistant to first- and/or second-generation ALK inhibitors.[7,8] Therefore, lorlatinib could be an effective treatment option for patients with ALK-positive NSCLC with CNS metastasis, who have been previously treated with ALK inhibitors.